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A B S T R A C T
Till now truncation mutations of voltage-gated sodium channel alpha subunit type I (SCN1A) gene were
mostly found in severe myoclonic epilepsy of infancy (SMEI) patients. In this research we ﬁrst identiﬁed
two novel de novo truncation mutations (S662X and M145fx148) in two patients whose phenotypes
were quitemilder comparedwith SMEI patients. One patientwas diagnosed as generalized epilepsywith
febrile seizures plus (GEFS+); the other had focal seizures. Both patients had good response to anti-
epileptic therapy (valproate or the combination of valproate and topiramate). Our ﬁndings extended the
utility of the SCN1A gene testing and further conﬁrmed the complex relationship between genotype and
phenotype of SCN1A mutations. Further work is needed to optimize the protocol for speciﬁc genetic
testing in children with epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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SCN1A, the neuronal voltage-gated sodium channel a1-subunit
gene, is thought as the most important pathogenic gene, whose
mutation can cause different types of epilepsy.1 Mutations of
SCN1A have been mainly identiﬁed in generalized epilepsy with
febrile seizures plus (GEFS+) and in severe myoclonic epilepsy of
infancy (SMEI) with occasional ﬁndings in other kinds of epilepsy,
for example, infantile spasms and Lennox–Gastaut syndrome.2–6
To date, most reported GEFS+ cases display autosomal-dominant
transmission with highly variable phenotypes. SMEI mostly arises
do novo, which is considered to be extreme severe phenotype of the
large SCN1A spectrum.7,8
The type of SCN1Amutationwas considered to be the reason for
that mutations in the same SCN1A gene resulted in such different
phenotypes. Truncaton mutations could cause complete loss of
sodium channel function, which resulted in the severe phenotype.9
However, these phenotype–genotype correlations were not abso-
lute. While in this research, we ﬁrst identiﬁed truncation
mutations in two patients whose phenotypes were quite milder
compared with SMEI patients.
2. Case reports
Respective parents of the two patients were unrelated and of
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doi:10.1016/j.seizure.2010.06.010Patient 1: The 16-year-old boy was born full time and his early
development was normal. At age 2 years, he had two episodes of
febrile generalized tonic-clonic seizures (GTCS) lasting about 5 min.
At 13 years of age, he had ﬁrst afebrile seizure. He complained of
uncomfortable feeling, then followed by secondary generalization.
Seizure frequency was four times a year. At 14 years the boy was
successfully treated with valproate and became seizure free. EEG
(performed at age 13 years) showed an almost normal background
with a little excessive b rhythms during wakefulness. Brain
magnetic resonance imaging (MRI) scans showed no abnormality.
Now he was a high-school student and his academic performance
was average. Hewas diagnosed asGEFS+. His fatherwas healthy but
his mother had several febrile seizures (FS) in her childhood. His
younger brother had one FS at 1 year old (Pedigree shown in Fig. 1).
Patient 2: The 2-year-old girl was born without any obvious
problems. At age 4 months old, she had her ﬁrst GTCS lasting for
3 min without any provoked factors. Seizure frequency was one
time 2 months. When she was 11 months old, she had complex
partial seizures (panic attack, occurring about 4–5 times per
month), which occasionally occurred during a febrile illness. Since
14 months old, she had secondarily GTCS, once every 2 weeks. At
16 months, she accepted the treatment with combination of
valproate and topiramate and became seizure free. Video-EEG
(performed at age 16months) showed almost normal, with regular
high aptitude u waves and 1.5–2.0 Hz slow activity in the frontal/
middle left temporal area. MRI (done at age 8months) was normal.
So far her psychomotor development was normal. The family
history of FS or epilepsy was negative.
Genomic DNA was obtained from blood samples of the both
patients and their respective parents. The parents gave writtenvier Ltd. All rights reserved.
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Fig. 1. Pedigree, DHPLC and sequencing analysis of patient 1. (A) Pedigree. (B) DHPLC chromatograms of all family members. Arrow showed the mutation peak. (C) Partial
nucleotide sequences of exon 11 of SCN1A, showing the heterozygous A > C substitution that corresponds to the truncation mutation S662X.
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Fig. 2. Pedigree, DHPLC and sequencing analysis of patient 2. (A) Pedigree. (B) DHPLC chromatograms of all family members. Arrow showed the mutation peak. (C) Partial
nucleotide sequences of exon 3 of SCN1A, showing the heterozygous deletion c.[AT]433-434del that corresponds to the truncation mutation M145fsX148.
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review board of the hospital. Methods for mutational analysis of
SCN1Awere described previously.10 The results of denaturing high
performance liquid chromatography (DHPLC) and sequencing
were shown in Figs. 1 and 2. Two do novo truncation mutations in
SCN1A were detected in the two patients respectively. For patient
1, genetic analysis detected a nucleotide change (c.1985C>A),
which led to premature termination at 662 in protein (S662X). In
patient 2, we detected a nucleotide change (c.[AT]433-434del),
which resulted in a frame-shift mutation (M145fsX148).
3. Discussion
Early previous studies have shown that truncationmutations of
SCN1Awere exclusively associated to SMEI.11–13 An exception was
found later in a patient with cryptogenic focal epilepsy (CFE),
which was considered as one subtype of infantile epileptic
encephalopathies.14 Generally speaking, truncation mutation of
SCN1A led to serious phenotypes. However, in rare familial SMEI
cases, SCN1A truncation mutation was found to be transmitted by
the asymptomatic or mildly symptomatic parent.15 These ﬁndingsemphasized the difﬁculty of predicting the SMEI phenotype based
on the ﬁnding of SCN1A mutation, also suggested signiﬁcant roles
of genetic backgrounds or environmental modiﬁers.
In the present study, two truncation mutations were found to
associate with milder epilepsy other than SMEI. For patient 1,
because his mother and younger brother had FS, we suspected the
mother might transmit the pathogenic gene to her sons. To our
surprise, the patient carried the truncation mutation while his
relatives did not, whichmay be explained by the polygenetic factors
of FS.16 He was diagnosed as GEFS+. For patient 2, she had partial
seizures, and her initial seizures were not related to febrile
circumstances, which was corresponding to CFE.14 However, till
now she did not show intellectual disability and had good response
to anti-epileptic drugs (AEDs),whichwas not consistentwith CFE.14
Although the seizures occurred occasionally during febrile illness,
close relationship between the seizures and febrile events was not
deﬁned, probably due to the well control of seizures. Otherwise a
diagnosis of partial epilepsy with febrile seizures might be
considered.10 The ﬁnal diagnosis may be conﬁrmed by the later
follow-up.Our results indicate thatmutations leading to a truncated
protein are not necessarily speciﬁc for the diagnosis of SMEI. Then
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only mild phenotype should cause our attention in future studies.
It has been a few years since the application of SCN1A gene test
in GEFS+/SMEI patients. It is of great importance to determinewhat
kind of patients needs such a gene test. The present two cases
suggested the isolated milder cases might also be candidates for
SCN1A gene test. Our ﬁndings are clinically signiﬁcant in two
aspects. Firstly, although seizure aggravations induced by AEDs
(lamotrigine, carbamazepine, and probably phenytoin) are known
for SMEI patients,17–20 the danger of seizure aggravations in
isolated milder cases is usually ignored. Recently we found that
sodium channel blockers could cause seizure aggravation in
patients with SCN1A mutations associated with loss of function.10
Therefore, these milder cases with the same genetic basis may also
have the similar AEDs response. An early genetic diagnosis will
help clinicians to choose AEDs correctly, which may be critical in
preventing seizure aggravation and the generation of intractable
epilepsy. Our two cases both had good response to the valproate
(or combination with topiramate), which was also in accordance
with the AEDs response of SMEI patients.21,22 Secondly, comparing
with SMEI patients who have few chances to have offspring
because of devastating intractable epilepsy, milder cases may have
more chances to have their own children. The genetic diagnosis,
even prenatal diagnosis, is thus required for genetic counseling.
Overall, the present study demonstrated two novel, do novo
SCN1A truncation mutations in milder cases other than SMEI,
which extended the utility of the SCN1A gene testing and further
conﬁrmed the complex relationship between genotype and
phenotype of SCN1Amutation. Further work is needed to optimize
the protocol for speciﬁc genetic testing in children with epilepsy.
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